Sanofi receives orphan status from EMA for rilzabrutinib
Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK)…
All articles by
-
-
Apertura signs multiple licensing agreements for TfR1 CapX tech
Apertura Gene Therapy has entered several licensing agreements to advance central nervous system (CNS) treatments using its transferrin receptor 1…
-
Amphastar and Anji make licence agreement for three new peptides
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…
-
AbbVie expands North Chicago API production with $195m investment
AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the expansion of its…
-
Sartorius to invest $3m for minority share in biotech start-up Nanotein
Sartorius Stedim Biotech has agreed to invest $3m in Nanotein Technologies, a US-based company engaged in the development of advanced…
-
Fosun and Expedition make $645m licensing deal for respiratory drug
Fosun Pharma's subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug,…
-
Japan MHLW approves Biostar’s angel stem cell therapy for autism
Biostar Stem Cell Technology Research Institute has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its…
-
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer
Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food and Drug…
-
MAXONA Pharma seeks FDA approval for pain relief MAX-001
MAXONA Pharmaceuticals has submitted an investigational new drug (IND) application seeking approval from the US Food and Drug Administration (FDA)…
-
CorMedix signs agreement to acquire Melinta for $300m
CorMedix, a biopharmaceutical company specialising in critical care products, has signed an agreement to acquire Melinta Therapeutics for $300m upfront.…